Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
收藏NIAID Data Ecosystem2026-05-01 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/58600
下载链接
链接失效反馈官方服务：
资源简介：
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
This was a phase II study of cadonilimab in combination with bevacizumab and FOLFOXIRI as first line therapy for metastatic microsatellite stable (MSS) colorectal cancer. The goal of this clinical trial is to evaluated the efficacy and safety.
创建时间：
2023-05-15
